Clinical trial
Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor…
NCT00499200 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00499200 |
|---|---|
| Title | Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy |
| Official title | A Positron Emission Tomography Study to Assess the Level and Duration of Occupancy of Serotonin-1A Receptors Produced by Single Oral Doses of SRA-444 in Healthy Elderly Subjects and in Subjects With Alzheimer Disease |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | SRA-444 |
| Enrollment | 42 |
| Start date | Oct 1, 2007 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Jul 11, 2007 |
| Last update posted | Jul 9, 2008 |
| Countries | Sweden |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: